Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth...
-
CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
-
ATLAS™ identifies naturally occurring neoantigen-specific inhibitory T cell responses that are augmented after vaccination Inhibitory T cell responses exacerbate tumor growth CAMBRIDGE, Mass., Nov. ...
-
Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapy Confirm positive GEN-009 clinical...
-
Generated unprecedented 98% GEN-009 immune response frequency with ATLAS™Continued advancement of GEN-011, expect to file an IND in first half of 2020Entered into a common stock purchase agreement for...
-
CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third...
-
Additional positive GEN-009 clinical immunogenicity data driven by ATLAS™ to be presented at ESMO Company to present at the Cantor Fitzgerald 2019 Global Healthcare Conference CAMBRIDGE, Mass.,...
-
CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip...
-
Initiated Part B of Phase 1/2a clinical trial of neoantigen vaccine candidate GEN-009;Plans to present additional GEN-009 immunogenicity data at ESMO 2019 Conference call today at 8:30 am ET ...
-
CAMBRIDGE, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, will host its second-quarter...